Holen Sie sich die Stockscreener-App
10.19
7.28%
-0.80
Handel nachbörslich:
10.05
-0.14
-1.37%
Schlusskurs vom Vortag:
$10.99
Offen:
$11.03
24-Stunden-Volumen:
2.13M
Relative Volume:
1.03
Marktkapitalisierung:
$1.17B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-3.4426
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
-4.23%
1M Leistung:
-8.69%
6M Leistung:
-38.73%
1J Leistung:
-51.41%
1-Tages-Spanne:
$10.10
$11.11
1-Wochen-Bereich:
$9.665
$11.48
52-Wochen-Spanne:
$9.66
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
10.19 | 1.17B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals Appoints Nicholas Botwood Chief Medical Officer - marketscreener.com
B. Riley Has Positive Outlook for SNDX Q2 Earnings - MarketBeat
SNDX Appoints New Head of Research and Development | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as - GlobeNewswire
I Have a Prescription for These Two Biopharmas That Fell After Earnings - TheStreet Pro
Synlogic (SNDX) to Attend Meeting Hosted by B. Riley in New York - GuruFocus
Granahan Investment Management LLC Has $11.97 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Cubist Systematic Strategies LLC Invests $4.73 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Crestline Management LP Has $9.43 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals' (SNDX) Buy Rating Reaffirmed at Guggenheim - MarketBeat
Scotiabank Issues Positive Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Voya Investment Management LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Bayesian Capital Management LP Invests $370,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Marshall Wace LLP Sells 977,280 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Algert Global LLC Buys 310,634 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - Yahoo Finance
Syndax Announces Participation in May Investor Conferences - The Manila Times
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results - simplywall.st
Avidity Partners Management LP Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX: Syndax Reveals Significant Phase 2 Trial Results for Revumenib | SNDX Stock News - GuruFocus
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $36.20 - MarketBeat
Syndax Announces Publication of Pivotal Revumenib Data in - GlobeNewswire
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood - Yahoo Finance
Syndax signals $4B total market opportunity with Revuforj expansion into frontline settings - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2025 Earnings Call Transcript - Insider Monkey
Syndax Pharmaceuticals’ Optimistic Q1 2025 Earnings Call - TipRanks
SNDX: Scotiabank Raises Price Target on Syndax Pharmaceuticals | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenhei - GuruFocus
Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenheim | SNDX Stock News - GuruFocus
Scotiabank raises Syndax stock target to $17 on strong sales By Investing.com - Investing.com Canada
Syndax (SNDX) Price Target Increased by BofA Following Promising Updates | SNDX Stock News - GuruFocus
BofA raises Syndax stock price target to $26 on strong Q1 update - Investing.com Canada
Syndax Pharmaceuticals Q1 Loss Widens - marketscreener.com
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highligh - GuruFocus
SNDX Reports Strong Revenue and Cash Position, Focuses on Growth - GuruFocus
Syndax Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Earnings call transcript: Syndax Pharmaceuticals beats Q1 2025 EPS estimates - Investing.com Canada
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Syndax Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha
Syndax: Q1 Earnings Snapshot - MySA
Syndax Pharmaceuticals earnings beat by $0.26, revenue topped estimates - Investing.com Canada
Syndax Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.98 Beats Estimates, Revenue Surges to $20 Million - GuruFocus
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):